Introduction {#S1}
============

Lipids are important factors in bacterial infections. They serve as energy source, structural components and are involved in the immune response. Like many bacteria, *Chlamydia trachomatis* is able to synthesize most phospholipids except for sphingomyelin, cholesterol and phosphatidylcholine. Sphingomyelin is mainly produced by eukaryotic cells thus; the detection of sphingomyelin inside chlamydial cells was astonishing. This review summarizes recent advances in our understanding of how *Chlamydia* spp. acquire sphingolipids from the host cell and describes their functions for *Chlamydia* biology.

Clinics of *Chlamydia trachomatis* and *C. psittaci* Infections {#S2}
===============================================================

*Chlamydia trachomatis* strains can be divided into biovars. The trachoma biovar (serovars A-C) can cause trachoma, the leading cause of preventable blindness that is hyperendemic in many rural areas of Africa, Central and South America, Asia, Australia and the Middle East. Infections with the urogenital tract biovar (serovars D-K) are among the most frequently sexually transmitted bacterial infections world-wide. They affect mainly young adults and persons with multiple sex partners ([@B41]). Symptoms range from asymptomatic to urethritis and proctitis in both genders and cervicitis in females. In particular, untreated or re-occurring infections in women have been associated with severe outcomes including pelvic inflammatory diseases (PID), ectopic pregnancies and infertility. Furthermore, during pregnancy, untreated *C. trachomatis* infections are a risk factor of preterm birth, conjunctivitis and pneumonia of the newborn. *C. trachomatis* belonging to the lymphogranuloma venereum biovar (LGV, L1-L3) is also sexually transmitted and can cause urogenital or anorectal infections in humans that can be more invasive by disseminating to the lymph nodes ([@B15]).

*Chlamydia psittaci* is a zoonotic pathogen that causes respiratory disease in humans and avian species, also known as psittacosis or ornithosis ([@B27]; [@B28]). The agent was originally isolated from birds, but meanwhile it has been found in different mammalian hosts like cattle, horses and pigs ([@B33]). *C. psittaci* can be transmitted from domestic birds to humans by inhalation of aerosolized bacteria from the feces of infected avian species ([@B27]; [@B28]). In many cases *C. psittaci* infections remain undetected and undiagnosed due to unspecific symptoms (fever, chills, headache, malaise, myalgia) ([@B27]; [@B28]).

Biology of *Chlamydiacea*e {#S3}
==========================

Both *C. trachomatis* and *C. psittaci* belong to the family of *Chlamydiaceae*. A hallmark of all members of this family is their obligate intracellular, biphasic cycle of development that takes place in a membrane-bound compartment inside a eukaryotic host cell ([@B40]; [@B24]).

It is characterized by the switch between the extracellular, infectious elementary bodies (EBs) and the intracellular, non-infectious, metabolically active reticulate bodies (RBs) ([Figure 1](#F1){ref-type="fig"}). EBs are 0.3 μm in size and enter the host cell by receptor-mediated endocytosis or phagocytosis, involving bacterial adhesins, host cell receptors, and host-specific heparan proteoglycans ([@B15]). After internalization, EBs are found in vacuoles, termed inclusions that protect the bacteria from the immune response of the host cell. By releasing effector molecules into the host cell via a type III secretion system, the inclusion membrane is modified and can escape the phagolysosomal pathway ([@B38]). Within the inclusion, EBs differentiate into the osmotically instable RBs. These 1 μm small, structurally flexible bacteria divide asymmetrically ([@B42]; [@B1]). RBs synthesize a family of special proteins, the Inc proteins, which are unique to *Chlamydia* spp. and are integral parts of the bacterial inclusion membrane. They are important bacterial constituents of the inclusion-host cell interface and confer stability to the inclusion membrane ([@B35]; [@B58]). Inc proteins were originally identified in *C. psittaci*. They are a family of *Chlamydia*-specific proteins lacking sequence homology to any known proteins, or to themselves. Interestingly, genomic comparison of different *Chlamydia* strains showed that some Inc proteins are conserved between different species and others are species-specific. These non-conserved Inc proteins may be involved in tissue tropism ([@B12]; [@B34]).

![The chlamydial developmental cycle. The biphasic developmental cycle of *Chlamydia* spp. starts with the attachment and invasion of host cells by infectious elementary bodies (EBs). Within their membrane-bound vacuole, termed inclusion, EBs differentiate into metabolically active reticulate bodies (RBs). RBs undergo repeated cycles of replication before they finally re-differentiate into EBs. The life cycle ends with the release of EBs from the host cell by either host cell lysis or extrusion formation to start a new round of infection.](fcell-07-00223-g001){#F1}

At 16--20 h *post infection* (*p.i.*) some RBs start to transform back into EBs, while other RBs continue to replicate. Depending on chlamydial species and growth conditions, at 48--72 h *p.i.* both developmental stages are released from the host cell by either complete lysis of the host cell or by a mechanism called extrusion -- the release of the intact inclusion enveloped by host cell plasma membrane ([Figure 1](#F1){ref-type="fig"}; [@B25]). Freed EBs can infect neighboring host cells and start a new round of infection.

Sphingolipid Synthesis in Eukaryotic Cells {#S4}
==========================================

Sphingolipids are major integral components of eukaryotic cell membranes. They function as structural and signaling molecules that can regulate apoptosis, cellular proliferation and stress responses ([@B23]; [@B8]). Defects in sphingolipid metabolism have been linked to different diseases including carcinogenesis, cardiovascular and neurodegenerative diseases ([@B23]).

A sphingoid base linked to a specific fatty acid is the building block of the diverse family of sphingolipids. In sphingomyelin, this backbone is linked to a head group of phosphocholine whereas complex glycosphingolipids are generated by addition of a specific sugar residue. Sphingolipids are a family of structurally and functionally diverse lipids and are synthesized by three distinct pathways: (1) *de novo* synthesis, (2) sphingomyelinase pathways, and (3) salvage pathway that involve specific enzymes localized to distinct organelles inside the cell.

*De novo* sphingolipid synthesis begins with condensation of serine and palmitoyl coenzyme A (CoA) which takes place at the cytosolic leaflet of the endoplasmic reticulum (ER) catalyzed by the highly conserved palmitoyltransferase (SPTLC) ([@B61]; [@B8]; [@B21]). The product of SPTLC, 3-ketosphinganine, is further reduced by 3-ketosphinganine reductase (KDSR) and N-acylated by the action of fatty acid specific dihydroceramide synthases (CERS1-6). Finally, dihydroceramide is desaturated by dihydroceramide desaturase (DEGS) to generate ceramide. Ceramide represents the central precursor molecule of the sphingolipid metabolism, which in turn is used to generate several sphingolipids, like sphingomyelin, sphingosine or complex glycosphingolipids. Ceramide is then transported from the ER to the Golgi apparatus by vesicular trafficking or by transport proteins ([@B5]; [@B20]). Within the Golgi, ceramides are modified at the head-group position by adding phosphocholine and phosphate to produce sphingomyelin and ceramide 1-phosphate ([@B55]; [@B21]). Ceramide is converted to sphingomyelin by sphingomyelin synthases (SMS) located at the lumen of the *trans-Golgi* (SMS1 and SMS2) and at the plasma membrane (SMS2) ([@B55]; [@B60]). Precursor of complex glycosphingolipids, such as glucosylceramide and galactosylceramide, are formed by the addition of glucose and galactose residues in a glycosidic linkage to ceramide ([@B8]; [@B60]). Ultimately, sphingolipids and glycosphingolipids are transported through secretory pathways to plasma membranes and subcellular organelles.

Alternatively, ceramides can be generated by the breakdown of complex sphingolipids, termed salvage pathway ([@B26]). Sphingolipids and glycosphingolipids are degraded in acidic subcellular compartments, such as late endosomes and lysosomes, to form sphingosine ([@B26]). In contrast to ceramide, which is not capable to leave the lysosome, sphingosine is able to enter different cell compartments ([@B5]). Released sphingosine may re-enter sphingolipid pathways and is reused by the ceramide synthase to generate ceramides again via re-acylation ([@B26]).

The third pathway, termed sphingomyelinase pathway, occurs in the plasma membrane and endosome/lysosome systems ([@B60]; [@B56]). Within these compartments, sphingomyelin is converted to ceramide by acid sphingomyelinases ([@B26]). At plasma membranes, SMS2 adds phosphocholine head groups to ceramide, which leads to the production of sphingomyelin.

Sphingolipid Transport in *Chlamydia-*Infected Cells {#S5}
====================================================

Twenty four years ago, [@B19] showed that fluorescently labeled sphingomyelin is acquired by *C. trachomatis* from the host cell. Based on the observation that purified EBs contained fluorescent sphingomyelin the authors concluded that Golgi-derived sphingomyelin accumulates in bacteria rather than its precursor ceramide. Classical protein markers of the transport between the Golgi apparatus and the plasma membrane were not found in the inclusion membrane suggesting that a subset of Golgi-derived exocytic vesicles is targeted ([@B18]; [@B51]). *C. trachomatis* protein synthesis is required for this interaction and bacterial factors that mediate fusogenicity with sphingomyelin-containing vesicles seem to be continually replenished ([@B52], [@B53]). Shortly after these initial observations, quantitative analysis indicated that *C. trachomatis* membranes contain up to 4% of sphingolipids ([@B59]). Interfering with bacterial sphingolipid acquisition resulted in less infectious bacteria, leads to the formation of aberrant chlamydial forms and demonstrated the requirement of sphingolipid metabolism for reactivation after INFγ treatment of *C. trachomatis*-infected cells ([@B57]; [@B45]; [@B46]). Interestingly, synthesis of sphingomyelin from ceramide seems to be a prerequisite for sphingolipid uptake into the inclusion and into the bacteria, as a ceramide derivative that cannot be converted to sphingomyelin (1-*O*-methyl-ceramide) was not translocated across the inclusion membrane but rather accumulated around the inclusion ([@B4]). This ceramide derivative showed strong anti-chlamydial activity suggesting that *C. trachomatis* generates a sphingomyelin-producing compartment inside the host cell which is important for chlamydial growth ([@B4]; [@B49]). Surprisingly, a recent study suggests that sphingomyelin uptake by *Chlamydia* species is linked to host adaptation and/or virulence rather than to its obligate intracellular life style ([@B14]).

In recent years, vesicular and non-vesicular transport pathways were identified that were hijacked by *C. trachomatis* to obtain sphingolipids from the host cell ([Figure 2](#F2){ref-type="fig"}). These pathways are not redundant and play distinct roles during the chlamydial cycle of development. It has been shown that *C. trachomatis* can intercept vesicular transport routes from different organelles including Golgi mini-stacks or multivesicular bodies (MVBs). Transport of sphingolipid-containing vesicles derived from Golgi mini-stacks requires cellular GTPases RAB14, RAB6A and RAB11A, ARF1 and its guanine nucleotide exchange factor GBF1 ([@B22]; [@B16]). Interestingly, RAB14, RAB6A, and RAB11A appear to be important for *Chlamydia* progeny formation whereas ARF1 and GBF1 seem to be dispensable ([@B45]; [@B9]; [@B16]). The recruitment of RAB14-postive vesicles was shown to be controlled by the Akt signaling pathway, a pathway that is activated by *C. trachomatis* infections ([@B10]). Several other kinases have also been implicated in sphingomyelin transport to the *C. trachomatis* inclusion. These include SRC family kinase Fyn and serine/threonine kinases that have been identified in an RNAi screen and based upon inhibition by rotterlin, respectively ([@B54]; [@B36]). The precise mechanisms how rotterlin inhibits sphingomyelin uptake by *C. trachomatis* remains elusive as rotterlin appears to have multiple targets inside the host cell ([@B31]). In addition, sphingomyelin is transported from MVBs by RAB39 ([@B17]). The MVB marker protein CD63 has been detected inside C. trachomatis inclusion but its functional role remains elusive ([@B6], [@B7]). In contrast, much less is known for sphingolipid acquisition in *C. psittaci* infections ([Figure 2](#F2){ref-type="fig"}). For both species, infection results in fragmentation of the cellular Golgi apparatus into smaller Golgi mini-stacks thereby increasing Golgi surface ([@B22]; [@B27]). This phenotype has been shown to boost sphingolipid acquisition in *C. trachomatis* infections ([@B22]). In sum, multiple cellular processes contribute to sphingolipid acquisition in *Chlamydia* infections ([@B37]). How these factors regulate sphingolipid transport and influence the infection is currently not completely understood.

![Sphingolipid acquisition during *Chlamydia* infection. Acquisition of sphingolipids takes place by both vesicular and non-vesicular pathways and is ensured by interactions with several subcellular compartments and host cell proteins. Vesicular transport of sphingolipids to *C. trachomatis* is realized by rerouting vesicles from fragmented Golgi mini-stacks or multivesicular bodies, involving several RAB GTPases such as RAB6, RAB11, RAB14, and RAB39. Recruitment of RAB GTPases is thought to be mediated by Inc proteins and interaction of RAB11 with CT556 has been described ([@B35]). Non-vesicular routes to *C. trachomatis* include recruitment of SMS and the formation of ER/inclusion membrane contact sites that contain the ceramide transport protein CERT. In contrast, little is known for *C. psittaci*, except for fragmentation of the Golgi apparatus and recruitment of CERT.](fcell-07-00223-g002){#F2}

The recruitment of cellular proteins, especially RAB proteins, is species dependent ([@B11]). In the past, the localizations of RAB proteins were investigated during infection of different *Chlamydia* species and showed that a core subset of RAB proteins is recruited to the inclusion membrane of different *Chlamydia* species whereas a few RAB proteins are species-specific ([@B48]). Interestingly, although recruitment of a RAB protein is conserved between different *Chlamydia* species (Rab4 in *C. trachomatis* serovar L2 and D, *C. muridarum*, and *C. pneumoniae*), its identified bacterial interaction partner that is responsible for the interaction (CT229 in *C. trachomatis* serovar L2) has not been found in the other chlamydial species ([@B47]). This leaves a question mark on of how the mechanisms of functional recruitment differ between *Chlamydia* species.

Future research regarding the role of these different vesicular pathways in infections with different *Chlamydia* species, the identification of transported lipids and bacterial factors controlling these interactions is needed to understand the intricate relationship.

Cert-Dependent Acquisition of Sphingolipids and Beyond {#S6}
======================================================

New studies showed that *C. trachomatis* and *C. psittaci* hijack the cellular ceramide transport protein CERT to obtain ceramide from the host cell ([@B13]; [@B29]). CERT transfers ceramide from the ER to the Golgi apparatus in uninfected cells using the C-terminal START domain ([@B44]). Its N-terminal pleckstrin homology (PH) domain binds phosphatidylinositol-4-phosphate (PI4P) ([@B43]) at the *cis*-face of the Golgi apparatus and is linked with the ER due to its central FFAT motif binding VAPs (Vesicle-associated membrane protein-associated protein) ([@B32]). In *C. trachomatis*-infected cells, CERT is recruited to the inclusion membrane by interaction with IncD ([Figure 2](#F2){ref-type="fig"}). Targeted deletion of CERT domains showed that the FFAT motif is relevant for binding and co-recruiting VAPs to the inclusion membrane, but lack of the PH domain interrupts association to the inclusion ([@B3]). The interaction of IncD with CERT is driven by the charged and hydrophobic motif in its C-terminus as well as the charged motif in the N-terminus ([@B30]). These motifs are conserved in *C. trachomatis*, *C. suis*, *C. muridarum*, *C. caviae*, and *C. felis*. Also, the proximity of both domains and the possibility of forming homooligomers mediated by the transmembrane domain are necessary for increasing the affinity to CERT. After CERT recruitment to the inclusion membrane, ceramide is likely transported from the ER to the inclusion membrane at ER-inclusion contact sides where ceramide is subsequently converted into sphingomyelin by the also recruited host SMS2 ([Figure 2](#F2){ref-type="fig"}; [@B16]). IncD belongs to the non-conserved Inc proteins that are not found in all *Chlamydia* species, for example *C. psittaci*. Thus, it is currently not known how CERT is recruited to *C. psittaci* inclusions ([@B29]). In uninfected cells, the CERT PH domain binds to PI4P-enriched membranes in the *trans-Golgi* region. It has been suggested, that PI4P is present at *C. trachomatis* inclusion membranes and might thereby partially mediate CERT binding ([@B39]). Assuming that *C. psittaci* inclusions are PI4P positive, this mode of binding could be conserved between the different *Chlamydia* species. In addition, proteomic analysis of *C. trachomatis* inclusions revealed that VAPB, a binding partner of CERT is significantly enriched in the inclusion proteome ([@B2]). Whether VAPB is also associated with *C. psittaci* inclusions or if a currently unknown *C. psittaci* factor facilitates CERT recruitment still needs to be determined. Thus, future experiments are needed to reveal the nature of CERT binding to *C. psittaci* inclusions.

Sphingomyelin is one of the essential host-derived lipids that is incorporated into chlamydial membranes ([@B50]) and is described to play a role in bacterial replication and inclusion growth ([@B18]; [@B45]; [@B16]). Further evidence for this suggestion is that CERT recruitment is conserved among *Chlamydia* spp. ([@B29]). For *C. trachomatis* and *C. muridarum* it has been shown by RNA interference that CERT seems to be essential for the production of infectious progeny, indicating that CERT is a crucial factor in chlamydial development ([@B13]; [@B16]). Recent studies using CRISPR/Cas9-mediated CERT-knockout cells demonstrated that deficiency of CERT in *C. psittaci* infections also leads to decreased infectious progeny formation ([@B29]). Interestingly, CERT-knockout caused an increase of sphingolipid uptake by *C. psittaci* ([@B29]). This is in stark contrast to *C. trachomatis* infection that shows a drastic decrease in bacterial sphingolipid acquisition under CERT depletion. These findings possibly suggest a CERT-independent sphingolipid uptake pathway in *C. psittaci* infections. How sphingolipids are transported to *C. psittaci* in CERT-knockout cells is currently not known. The involvement of one or more novel factor/s of either bacterial and/or cellular origin that compensate for loss of CERT is likely. Besides that, these results underline that acquisition of sphingomyelin needs to be controlled by *Chlamydia* spp. and suggest that CERT might have additional roles in chlamydial development beyond sphingolipid transport, which need to be investigated in the future.

Summary and Outlook {#S7}
===================

Twenty four years after the initial observation that *C. trachomatis* can acquire sphingomyelin from the Golgi apparatus of the infected host cells a clearer picture is emerging on the molecular pathways used by different *Chlamydia* species to obtain sphingolipids. *Chlamydia* species use distinct, non-redundant pathways to obtain sphingolipids. These include vesicular and non-vesicular transport pathways. The characterization of CERT as a conserved factor in ceramide delivery to different *Chlamydia* species and the recruitment of the human SMS2 to the *C. trachomatis* inclusion suggests that at least *C. trachomatis* creates a novel sphingomyelin-producing compartment inside the infected host cells. Additionally, in *C. trachomatis* infections sphingomyelin is transported by distinct vesicles. For that purpose, *C. trachomatis* exploits cellular GTPases, including RAB and ARF proteins, and kinases to facilitate bacterial sphingomyelin acquisition from fragmented Golgi mini-stacks and MVBs. How vesicular and non-vesicular transport of sphingolipids is controlled by different *Chlamydia* species, how they process CERT-delivered ceramide, and how ceramide and sphingomyelin regulate chlamydial infections are just a few open questions. The development of novel tools including the genetic manipulation of *Chlamydia* species and the biochemical isolation of chlamydial inclusions now allows addressing these questions.
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